Citi upgraded Tandem Diabetes (TNDM) to Neutral from Sell with a price target of $10.35, up from $10. The firm sees a more balanced risk/reward with the shares down 34% since the Q2 report. Citi cites valuation for the upgrade.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes Care: Upgraded to Neutral/High Risk Amid Valuation and Acquisition Interest
- Arm initiated, Adobe downgraded: Wall Street’s top analyst calls
- Tandem Diabetes downgraded to Hold from Buy at Lake Street
- Tandem Diabetes price target lowered to $51 from $53 at Barclays
- Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities